Loading
Unlike weight-loss drugs, Ozempic is widely covered by insurance plans for treating diabetes. Patients rarely pay full price. However, Novo said its new offering will expand availability for those who don’t have coverage, giving them access to a more affordable version of the drug.
“While Ozempic is well covered in the US, let’s not forget that there are some patients who pay out-of-pocket for this vital medicine,” Dave Moore, Novo’s head of US operations, said in a statement. “We believe that if even a single patient feels the need to turn to potentially unsafe and unapproved knockoff alternatives, that’s one too many.”
The move follows a long, contentious fight over Ozempic’s price, during which lawmakers on both sides of the aisle used it as an example of how drugmakers charge much more for their medicines in the US than other parts of the world. Last year, Novo’s former Chief Executive Officer Lars Fruergaard Jorgensen was called before a Congressional committee to testify about the price of his company’s drugs.
Bloomberg
- For more: Elrisala website and for social networking, you can follow us on Facebook
- Source of information and images “brisbanetimes”“
